Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fed Condition Clear all

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Interventions: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Pain
Interventions: ADA Liquid Filled Capsules (Test Product), ADA Caplets (Reference Product), Advil Liqui-gels (Reference Product); Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: Emraclidine; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Healthy Volunteers
Interventions: Aramchol, Placebo; Drug
Lead sponsor: Galmed Pharmaceuticals Ltd; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Food Effect in Healthy Participants
Interventions: CRS3123 200 mg capsule; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Erectile Dysfunction
Interventions: ASP-001.1, ASP-001.1; Drug · Device
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 20 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: E2511, E2511 Matched Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pharmacokinetic
Interventions: Cebranopadol 200 μg tablet; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy
Interventions: PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: ABBV-668 IR, ABBV-668 ER; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Cocaine Use Disorder
Interventions: Original formulation EMB-001, New formulation EMB-001; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Hepatic Impairment, Healthy Participants
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Healthy
Interventions: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 100 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: vepdegestrant, esomeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Danicopan; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Congenital Gastrointestinal Disorders
Interventions: Human Milk; Other
Lead sponsor: Emory University; Other
Eligibility: 1 Minute to 1 Year
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Autoimmune Disorders
Interventions: Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Nausea, Vomiting
Interventions: Granisetron; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: amlodipine 10 mg tablet; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Search by objective public record fields.

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

An Open-Label Food Effect Study of Telotristat Etiprate

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

A Study of the Effects of Food and Age on Danicopan

Human Milk for Congenital Gastrointestinal Disorders

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions

Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions